Showing all 4 results
Baricitinib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Bioavailability Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
Active Ingredient Strength Primary Clinical Function Baricitinib USP/Ph.Eur. 2 mg The Standard RA Anchor: The primary maintenance dose for adult patients with moderate-to-severe Rheumatoid Arthritis. Baricitinib USP/Ph.Eur. 4 mg The Dermatology/Severe Payload: High-potency dose utilized for Alopecia Areata and severe Atopic Dermatitis protocols. Excipients Proprietary Matrix Bio-Synchronized System: Engineered to ensure a consistent pharmacokinetic profile (Tmax of approx. 1 hour) for predictable immune suppression. Hydroxy Chloroquine Sulfate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Heavy-Coated Tablet, packed exclusively in highly secure, light-blocking Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the photolabile active ingredient.
Active Ingredient Strength Primary Clinical Function Hydroxychloroquine Sulfate USP/Ph.Eur. 200 mg Global Rheumatology Standard: Base therapeutic unit for daily chronic maintenance in SLE and RA, allowing for exact mg/kg dosing based on ideal body weight to prevent toxicity. Excipients Dibasic Calcium Phosphate / Pregelatinized Starch / Magnesium Stearate / Polyethylene Glycol / Premium Titanium Dioxide Opadry Film Diluent / Binder / Lubricant / Heavy Opacifying Film-Coating (Engineered specifically to form an impenetrable light barrier against UV degradation, while completely masking the intensely bitter taste of the sulfate salt to ensure long-term patient compliance) *Pack Sizes: Bottles of 100 or 10×10 Blisters (Optimized specifically for strict 3-to-6 month chronic rheumatology dispensing regimens).
Leflunomide Tablets
FreeProduct Composition & Available Portfolio Strengths
We supply Leflunomide across the complete compendial strength matrix, enabling clinicians to manage both rapid initial loading cycles and long-term low-dose maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Leflunomide USP / BP / IP 10 mg Oral Solid Film-Coated Tablet Low-Dose Maintenance: Calibrated for mild-to-moderate maintenance blocks or patients exhibiting sensitive hepatic profiles. Leflunomide USP / BP / IP 20 mg Oral Solid Film-Coated Tablet The Core Commercial Volume: First-line international standard daily maintenance dose for active Rheumatoid and Psoriatic Arthritis. Leflunomide USP / BP / IP 100 mg Oral High-Mass Solid Tablet Initial Loading Regimen: High-potency format utilized exclusively for the rapid 3-day initial tissue saturation phase. Methotrexate Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Tablet, packed exclusively in highly secure, handler-protective Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the antimetabolite.
Active Ingredient Strength Primary Clinical Function Methotrexate USP/Ph.Eur. 2.5 mg Global Autoimmune Standard: The absolute foundational unit for Rheumatoid Arthritis and Psoriasis, allowing for highly precise, incremental dose titration. Methotrexate USP/Ph.Eur. 5 mg / 7.5 mg / 10 mg Escalated / Oncology Standard: Higher-dose units for severe, refractory autoimmune disease, Choriocarcinoma, and maintenance therapy in Acute Lymphoblastic Leukemia (ALL). Excipients Lactose Monohydrate / Maize Starch / Pregelatinized Starch / Magnesium Stearate Diluent / Binder / Disintegrant / Lubricant (Engineered specifically using high-containment wet granulation to prevent airborne cytotoxic dust generation during manufacturing, ensuring precise, even API distribution) *Pack Sizes: 10×10 Blisters or Bottles of 100 (Optimized specifically for strict, heavily monitored chronic dispensing regimens).
